NWL:NASDAQNewell Brands Inc. Analysis
Data as of 2026-06-09 - not real-time
$4.38
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its longer‑term moving averages, with the short‑term average under the medium‑term average, reinforcing a bearish technical stance. Momentum indicators show the relative strength index in the upper half of its scale, hinting at lingering buying pressure but not yet overbought. The MACD histogram has turned positive while the line remains below the signal, suggesting a tentative bullish shift that lacks confirmation. Volume has been trending upward, adding weight to recent price moves. Recent price action sits near the lower end of the recent range, with resistance near the upper end, framing a narrow trading corridor. The beta is well above one and month‑to‑month volatility is extreme, indicating the stock is highly sensitive to market swings.
Core sales have slipped year‑over‑year, and operating margins are thin, while the overall profit margin is negative. The company carries a debt load that dwarfs its equity, creating a leverage profile that is markedly risky. Cash flow from operations is modest and free cash flow is positive but limited relative to debt obligations. The dividend yield sits in the high single digits, yet the payout ratio exceeds earnings, raising doubts about sustainability. Valuation metrics paint a mixed picture: a low forward price‑to‑earnings suggests cheapness, but a discounted cash flow model places intrinsic value far below the market price, implying overvaluation. Analyst coverage is sparse and recent downgrades temper optimism, while the stock’s upside potential appears constrained by the bearish technical backdrop.
Core sales have slipped year‑over‑year, and operating margins are thin, while the overall profit margin is negative. The company carries a debt load that dwarfs its equity, creating a leverage profile that is markedly risky. Cash flow from operations is modest and free cash flow is positive but limited relative to debt obligations. The dividend yield sits in the high single digits, yet the payout ratio exceeds earnings, raising doubts about sustainability. Valuation metrics paint a mixed picture: a low forward price‑to‑earnings suggests cheapness, but a discounted cash flow model places intrinsic value far below the market price, implying overvaluation. Analyst coverage is sparse and recent downgrades temper optimism, while the stock’s upside potential appears constrained by the bearish technical backdrop.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- bearish SMA alignment
- negative profit margin
- high leverage
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- potential MACD reversal
- low forward PE
- dividend yield attractiveness if sustained
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- structural brand portfolio
- possible improvement in core sales
- ongoing debt reduction efforts
Key Metrics & Analysis
Financial Health
Revenue Growth-1.10%
Profit Margin-3.91%
P/E Ratio6.6
ROE-11.17%
ROA2.73%
Debt/Equity243.13
P/B Ratio0.8
Op. Cash Flow$244.0M
Free Cash Flow$432.6M
Technical Analysis
TrendBearish
RSI63.5
Support$3.20
Resistance$4.49
MA 20$3.71
MA 50$3.92
MA 200$4.30
MACDBullish
VolumeIncreasing
Fear & Greed Index85.57
Valuation
Fair Value$0.36
Target Price$4.94
Upside/Downside12.86%
GradeOvervalued
TypeValue
Dividend Yield6.65%
Risk Assessment
Beta1.59
Volatility78.92%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.